Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter study of florbetapir (18F) PET imaging in healthy volunteers, MCI and Alzheimer's disease
jRCT2080221935Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Florbetapir in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Eli Lilly and Company.
02
Drugs
Florbetapir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on jRCT2080221935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221935.